| Project/Area Number |
24659258
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
NISHINA Kazutaka 東京医科歯科大学, 大学院・医歯学総合研究科, メディカルフェロー (60622529)
|
|---|
| Project Period (FY) |
2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
|
|---|
| Keywords | 遺伝子診断 / 治療 / アンチセンス核酸 / 核酸医薬 / ドラッグデリバリー |
|---|
| Research Abstract |
Here we developed a new class of exceptionally potent antisense oligonucleotides (ASOs) that are hybridized with complementary RNA (cRNA) and conjugated with a ligand. At first, we optimized the chemical modifications of cRNA. Secondly, tocopherol-conjugated ASO (Toc-dsASO) reduced multiple target sequence including mouse apolipoprotein B and human transthyretin. Finally, we showed the liver specific delivery of Toc-dsASO using IVIS imaging system.
|
